Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.61 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16382729 | 0.87 | NR4A2 (0.50) | NR4A2PIM3PIM1CHEK1ABL1 | |
| SCHEMBL7497434 | 0.86 | PIM3 (0.55) | NR4A2PIM3PIM1CHEK1CREBBP | |
| SCHEMBL2589245 | 0.82 | NR4A2 (0.60) | NR4A2PIM3PIM1CREBBPKDM4E | |
| SCHEMBL31480354 | 0.81 | PIM3 (0.50) | NR4A2PIM3PIM1CHEK1CREBBP | |
| SCHEMBL22587514 | 0.81 | PIM3 (0.50) | NR4A2PIM3PIM1CHEK1CREBBP | |
| SCHEMBL14774594 | 0.81 | PIM3 (0.50) | NR4A2PIM3PIM1CHEK1ABL1 | |
| SCHEMBL2588280 | 0.81 | PIM3 (0.50) | NR4A2PIM3PIM1CREBBPKDM4E | |
| SCHEMBL28730919 | 0.80 | NR4A2 (0.50) | NR4A2PIM3PIM1CHEK1ABL1 | |
| SCHEMBL15797513 | 0.80 | P2RX7 (0.54) | NR4A2PIM3PIM1CHEK1ABL1 | |
| SCHEMBL27205515 | 0.80 | CSNK2A2 (0.46) | NR4A2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-103347874-A | Dimeric iap inhibitors | NOVARTIS AG | 2013-10-09 | — | — | CN | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-6906096-B2 | 4,7-Disubstituted indoles and methods of making | IRM LLC (BM) | 2005-06-14 | — | — | US | disclosed |
| US-20040110944-A1 | 4,7-Disubstituted indoles and methods of making | IRM LLC (BM) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014294-A2 | 4,7-DISUBSTITUTED INDOLES AND METHODS OF MAKING | IRM LLC (BM) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110944-A1 | 4,7-Disubstituted indoles and methods of making | IDO1, IDO2, INMT | NR4A2 1712/4885PIM3 453/4885PIM1 900/4885 |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885PIM3 863/4885PIM1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.